CSA-131 (Kinnear Pharma)
Pseudomonas aeruginosa infections in Cystic Fibrosis
Pre-clinical/ResearchActive
Key Facts
Indication
Pseudomonas aeruginosa infections in Cystic Fibrosis
Phase
Pre-clinical/Research
Status
Active
Company
About N8 Medical
N8 Medical is a private, clinical-stage company developing antimicrobial coatings for medical devices to combat HAIs and antimicrobial resistance (AMR). Its lead CeraShield-coated endotracheal tube has received FDA Breakthrough Device designation and is cleared for use in several ex-US markets, with FDA approval anticipated. The company leverages significant non-dilutive funding through NIH SBIR grants and is structured under a holding company, N8 Biosciences, with a therapeutic drug development subsidiary, Kinnear Pharmaceuticals.
View full company profileTherapeutic Areas
Other Pseudomonas aeruginosa infections in Cystic Fibrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| AP-PA02 | Armata Pharmaceuticals | Phase 1b/2a |